TNSN07482A1 - NOVEL INJECTABLE COMPOSITIONS AND PROCESS FOR THE PREPARATION OF SAID COMPOSITIONS - Google Patents
NOVEL INJECTABLE COMPOSITIONS AND PROCESS FOR THE PREPARATION OF SAID COMPOSITIONSInfo
- Publication number
- TNSN07482A1 TNSN07482A1 TNP2007000482A TNSN07482A TNSN07482A1 TN SN07482 A1 TNSN07482 A1 TN SN07482A1 TN P2007000482 A TNP2007000482 A TN P2007000482A TN SN07482 A TNSN07482 A TN SN07482A TN SN07482 A1 TNSN07482 A1 TN SN07482A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pain
- compositions
- conditions
- inflammatory
- cox
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000007972 injectable composition Substances 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 4
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000004550 Postoperative Pain Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000008765 Sciatica Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 201000005671 spondyloarthropathy Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des compositions pharmaceutiques injectables, nouvelles et hautement stables, qui comprennent au moins un inhibiteur de la cyclooxygénase-II (COX-II) ou un anti-inflammatoire non stéroïdien (AINS) ou un inhibiteur de COX/LOX ou leurs formes tautomères, analogues, isomères, polymorphes, solvates, promédicaments ou sels de ces derniers comme principe actif approprié à une administration parentérale, de préférence, par voie intramusculaire (IM) ou intraveineuse (IV). L'invention concerne également un procédé de préparation de ces compositions et des méthodes thérapeutiques d'utilisation de ces compositions. Les compositions injectables analgésiques et anti-inflammatoires selon l'invention sont très utiles chez les mammifères, notamment les humains, pour le traitement d'états douloureux aigus tels qu'un ou plusieurs des états suivants : traumatismes postopératoires, douleur associée au cancer, blessures de sport, migraine, douleur neurologique et douleur associée à la sciatique et à la spondylarthrite et à des maladies analogues et/ou des états de douleur chronique et/ou divers états inflammatoires douloureux, tels que la douleur postopératoire, la dysménorrhée primaire et l'arthrose douloureuse, et/ou d'autres troubles associés, tels que l'inflammation, la fièvre, l'allergie ou des états analogues.Novel and highly stable injectable pharmaceutical compositions comprising at least one cyclooxygenase-II (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX / LOX inhibitor or forms thereof are provided. tautomers, analogs, isomers, polymorphs, solvates, prodrugs or salts thereof as an active ingredient suitable for parenteral administration, preferably, intramuscularly (IM) or intravenously (IV). The invention also relates to a process for the preparation of these compositions and to therapeutic methods for using these compositions. The injectable analgesic and anti-inflammatory compositions according to the invention are very useful in mammals, in particular humans, for the treatment of acute pain states such as one or more of the following states: postoperative traumas, cancer-related pain, wounds sports, migraine, neurological pain and pain associated with sciatica and spondyloarthritis and similar diseases and / or chronic pain conditions and / or various painful inflammatory conditions, such as postoperative pain, primary dysmenorrhea and painful osteoarthritis, and / or other associated disorders, such as inflammation, fever, allergy or similar conditions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1357DE2005 | 2005-05-27 | ||
| PCT/IN2006/000177 WO2006126214A2 (en) | 2005-05-27 | 2006-05-25 | Injectable compositions and process for preparation of such compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN07482A1 true TNSN07482A1 (en) | 2009-03-17 |
Family
ID=36917368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2007000482A TNSN07482A1 (en) | 2005-05-27 | 2007-12-21 | NOVEL INJECTABLE COMPOSITIONS AND PROCESS FOR THE PREPARATION OF SAID COMPOSITIONS |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1895983A2 (en) |
| JP (1) | JP2008542260A (en) |
| KR (1) | KR20080016689A (en) |
| CN (1) | CN101217939A (en) |
| AU (1) | AU2006250765A1 (en) |
| BR (1) | BRPI0611170A2 (en) |
| CA (1) | CA2609242A1 (en) |
| CR (1) | CR9616A (en) |
| EA (1) | EA200702646A1 (en) |
| MX (1) | MX2007014862A (en) |
| NO (1) | NO20076468L (en) |
| RS (1) | RS20070461A (en) |
| TN (1) | TNSN07482A1 (en) |
| WO (1) | WO2006126214A2 (en) |
| ZA (1) | ZA200711068B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101693049B1 (en) | 2007-09-07 | 2017-01-04 | 유나이티드 세러퓨틱스 코오포레이션 | Buffer solutions having selective bactericidal activity aganist gram negative bacteria and methods of using same |
| KR101864559B1 (en) * | 2009-03-12 | 2018-06-04 | 큠버랜드 파마슈티컬즈 인코포레이티드 | Administration of intravenous ibuprofen |
| US8871810B2 (en) | 2009-07-15 | 2014-10-28 | Cumberland Pharmaceuticals Inc. | Treating critically ill patients with intravenous ibuprofen |
| CN102335114B (en) * | 2010-07-23 | 2015-07-15 | 重庆医药工业研究院有限责任公司 | Stable ibuprofen arginine injection and preparation method thereof |
| CN102370615B (en) * | 2010-08-19 | 2013-09-04 | 四川科伦药物研究有限公司 | Ibuprofen injection preparation and preparation method thereof |
| TW201322979A (en) | 2011-10-18 | 2013-06-16 | Raqualia Pharma Inc | Pharmaceutical composition |
| CN102512383A (en) * | 2011-12-25 | 2012-06-27 | 天津市嵩锐医药科技有限公司 | Parecoxib sodium pharmaceutical composition for injection |
| US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| CN103372216B (en) * | 2012-04-26 | 2015-05-06 | 北京京卫燕康药物研究所有限公司 | Solid medical composition containing celecoxib |
| TWI646091B (en) | 2012-12-28 | 2019-01-01 | 日商衛斯克慧特股份有限公司 | Salt and crystal form |
| US20140187635A1 (en) | 2012-12-28 | 2014-07-03 | Themis Medicare Limited | Diclofenac compositions |
| US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
| CN103263385B (en) * | 2013-05-17 | 2016-04-27 | 江苏正大清江制药有限公司 | A kind of celecoxib long-acing nano injection and preparation method thereof |
| TN2017000232A1 (en) * | 2014-12-20 | 2018-10-19 | Troikaa Pharmaceuticals Ltd | Injectable formulations of paracetamol |
| WO2016170401A1 (en) * | 2015-04-20 | 2016-10-27 | Umedica Laboratories Pvt. Ltd | Novel injectable composition of diclofenac sodium |
| CN107303266B (en) * | 2016-04-18 | 2020-09-08 | 重庆润泽医药有限公司 | Levo-oxiracetam injection and preparation method thereof |
| CN107303264A (en) * | 2016-04-18 | 2017-10-31 | 重庆润泽医药有限公司 | Non-foam levo-oxiracetam parenteral solution and preparation method thereof |
| FR3077984B1 (en) * | 2018-02-16 | 2020-02-21 | Vetoquinol Sa | MULTI-PURPOSE COMPOSITION OF TORASEMIDE |
| CN109498852B (en) * | 2018-12-29 | 2022-06-24 | 广州噢斯荣医药技术有限公司 | Biodegradable material for treating orthopedic diseases and application thereof |
| CN111103381A (en) * | 2019-12-25 | 2020-05-05 | 南京希麦迪医药科技有限公司 | Method for determining nimesulide concentration in human plasma by liquid chromatography-mass spectrometry |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389681A (en) * | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| IT1283252B1 (en) * | 1996-03-15 | 1998-04-16 | Pulitzer Italiana | SOLUTIONS OF PIROXICAM INJECTABLE BY PARENTERAL WAY |
| IN187306B (en) * | 1998-01-12 | 2002-03-23 | Panacea Biotec Ltd | |
| PE20021017A1 (en) * | 2001-04-03 | 2002-11-24 | Pharmacia Corp | RECONSTITUABLE PARENTERAL COMPOSITION |
| WO2004014431A1 (en) * | 2002-08-12 | 2004-02-19 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
-
2006
- 2006-05-25 RS RSP-2007/0461A patent/RS20070461A/en unknown
- 2006-05-25 EP EP06756263A patent/EP1895983A2/en not_active Withdrawn
- 2006-05-25 AU AU2006250765A patent/AU2006250765A1/en not_active Abandoned
- 2006-05-25 CN CNA2006800250937A patent/CN101217939A/en active Pending
- 2006-05-25 JP JP2008513009A patent/JP2008542260A/en not_active Withdrawn
- 2006-05-25 KR KR1020077030585A patent/KR20080016689A/en not_active Ceased
- 2006-05-25 ZA ZA200711068A patent/ZA200711068B/en unknown
- 2006-05-25 BR BRPI0611170-0A patent/BRPI0611170A2/en not_active IP Right Cessation
- 2006-05-25 EA EA200702646A patent/EA200702646A1/en unknown
- 2006-05-25 CA CA002609242A patent/CA2609242A1/en not_active Abandoned
- 2006-05-25 MX MX2007014862A patent/MX2007014862A/en not_active Application Discontinuation
- 2006-05-25 WO PCT/IN2006/000177 patent/WO2006126214A2/en not_active Ceased
-
2007
- 2007-12-14 NO NO20076468A patent/NO20076468L/en not_active Application Discontinuation
- 2007-12-19 CR CR9616A patent/CR9616A/en not_active Application Discontinuation
- 2007-12-21 TN TNP2007000482A patent/TNSN07482A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006126214A3 (en) | 2007-06-07 |
| ZA200711068B (en) | 2009-03-25 |
| NO20076468L (en) | 2008-02-27 |
| BRPI0611170A2 (en) | 2010-08-17 |
| WO2006126214A2 (en) | 2006-11-30 |
| MX2007014862A (en) | 2008-02-21 |
| EP1895983A2 (en) | 2008-03-12 |
| EA200702646A1 (en) | 2008-06-30 |
| AU2006250765A1 (en) | 2006-11-30 |
| CA2609242A1 (en) | 2006-11-30 |
| JP2008542260A (en) | 2008-11-27 |
| CN101217939A (en) | 2008-07-09 |
| CR9616A (en) | 2008-10-30 |
| RS20070461A (en) | 2008-11-28 |
| KR20080016689A (en) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN07482A1 (en) | NOVEL INJECTABLE COMPOSITIONS AND PROCESS FOR THE PREPARATION OF SAID COMPOSITIONS | |
| BR0008060A (en) | Cyclooxygenase-2 inhibitory compositions having rapid onset of therapeutic efficacy | |
| UY26977A1 (en) | IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | |
| MA32070B1 (en) | Fusion-bonded heterocyclic derivatives and methods of use thereof | |
| TNSN99223A1 (en) | PHARMACEUTICAL COMPOSITIONS OF CELECOXIB, PROCESSES FOR THEIR PREPARATION AND METHODS OF TREATMENT USING THE SAME | |
| FR2364030A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON ANTHOCYANIDINES AND PROCESS FOR THEIR PREPARATION | |
| ATE409458T1 (en) | LIQUID DOSAGE FORMS FOR THE PREVENTION AND TREATMENT OF MUCOUS AFFECTIONS | |
| MA26700A1 (en) | PHARMACEUTICAL FORMULATIONS OF CONTROLLED RELEASE cGMP PDE-5 INHIBITORS AND PROCESS FOR THEIR PREPARATION. | |
| MA34474B1 (en) | AGONISTS OF GPR40 | |
| MA28778B1 (en) | RISEDRONATE COMPOSITIONS AND METHOD OF USE THEREOF | |
| MA38576A1 (en) | Colchicine extended-release formulations and methods of using the same | |
| DE60110185D1 (en) | Composition and method for parenteral administration of ibuprofen D, L-, or L-lysinate | |
| BRPI0720351A2 (en) | combination therapy for lower urinary tract disorders with a2o and aines ligands. | |
| EA200500941A1 (en) | MEANS FOR TREATING JOINT DISEASES | |
| BR9504375A (en) | Use of a compound pharmaceutical formulation and treatment method | |
| MX393732B (en) | CURCUMIN AND BASIC AMINO ACIDS COMPOUNDS. | |
| MX2025005933A (en) | 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection | |
| EA200500942A1 (en) | MEANS FOR TREATING JOINT DISEASES | |
| ATE480229T1 (en) | ORAL PHARMACEUTICAL COMPOSITION FOR TREATING A COX-2-MEDIATED DISEASE | |
| PA8579701A1 (en) | BETA-LACTAMASA INHIBITOR PROFARMACO | |
| MA27157A1 (en) | METHOD FOR THE TREATMENT OF BONE CONDITIONS. | |
| ES2284970T3 (en) | AMINA 1,2- AND 1,3-DIOL COMPOUNDS AND ITS USE FOR THE TREATMENT OF ALZHEIMER. | |
| JP2003520199A5 (en) | ||
| DE60028787D1 (en) | METHOD FOR TREATING INJURY TO THE TRAUMATED BRAIN WITH NON-STEROID INFLAMMATORY MEDICAMENTS | |
| WO2020036478A3 (en) | Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses |